<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1434">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326790</url>
  </required_header>
  <id_info>
    <org_study_id>906295542</org_study_id>
    <nct_id>NCT04326790</nct_id>
  </id_info>
  <brief_title>The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention</brief_title>
  <acronym>GRECCO-19</acronym>
  <official_title>The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on data regarding the effect of colchicine on the inflammasome NLP3 and microtubule
      formation and associations thereof with the pathogenetic cycle of SARS-COV-2, the question
      arises whether colchicine, administered in a relatively low dose, could potentially have an
      effect the patients' clinical course by limiting the myocardial necrosis and pneumonia
      development in the context of COVID-19. If present, this effect would be attributed to its
      potential to inhibit inflammasome and (less probably) to the process of SARS-CoV-2
      endocytosis in myocardial and endothelial respiratory cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patient-level randomization scheme</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&amp;D committee</measure>
    <time_frame>3 weeks</time_frame>
    <description>Time to clinical deterioration (2 levels in the WHO R&amp;D Blueprint scale)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal concentration of cardiac troponin</measure>
    <time_frame>10 days</time_frame>
    <description>Maximal concentration of high-sensitivity cardiac troponin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Corona Virus Disease 19 (Covid 19)</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine, on top of standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment, including all medications recommedned by the National Public Health Organization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Low-dose colchicine treatment, 0.5 mg bid</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Standard treatment</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients &gt;18 years old with laboratory confirmed SARS-CoV-2 infection (RT PCR) AND body
        temperature &gt;37.5 degrees centigrade AND at least two of: i. sustained coughing, ii.
        sustained throat pain, iii. anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2&lt;95 mmHg.

        Exclusion Criteria:

          -  pregnancy, lactation;

          -  known hypersensitivity to colchicine

          -  known hepatic failure

          -  eGFR&lt;20 ml/min

          -  clinical estimation that the patient will require mechanical respiratory support in
             less than 24 hours

          -  any clinical estimation of the attending physician under which the patient shall be
             excluded

          -  QTc &gt; 450 msec (colchicine is not known to significantly prolong QTc, but may interact
             with other medications which prolong QTc).

          -  participation in another clinical trial

          -  under colchicine treatment for other indications

          -  patient who is not likely to comply to study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Spyridon Deftereos</last_name>
    <phone>00306944699901</phone>
    <email>spdeftereos@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AHEPA Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Gibraltar</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Gibraltar</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Spyridon Deftereos</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

